Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension follow-up of oral tolvaptan in pediatric hyponatremia
2013-002810-11Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in hyponatraemia, Euvolemic hyponatremia and Hyperhydration, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change from baseline in serum sodium while tolvaptan is being administered. Started Nov 2014; status: terminated.
02
Drugs
tolvaptan
03
Conditions
hyponatraemiaEuvolemic hyponatremiaHyperhydration
Beyond the preview
Go deeper on 2013-002810-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002810-11.